Biotechnology

124 articles in this category (Page 5 of 6)

Stock Weather AIBiotechnologyAnalyst Sentiment

Legend Biotech – 2025-12-08 - Increase Confidence 6/10

Despite negative free cash flow and ultra-expensive valuation, overwhelming Carvykti demand and strong analyst consensus signal near-term upside.

Dec 8, 2025LEGN

Stock Weather AIBiotechnologyClinical Trials

Terns Pharmaceuticals – 2025-12-08 - increase Confidence 8/10

Strong cash runway into 2028 meets breakthrough Phase 1 data showing 75% MMR in CML, fueling near-term upside for TERN.

Dec 8, 2025TERN

Stock Weather AIBiotechnologyClinical-Stage Pharma

Wave Life Sciences – 2025-12-08 - Increase Confidence 7/10

Positive pipeline data and strong analyst sentiment outweigh near-term dilution risk from $250M share offering, signaling short-term upside.

Dec 8, 2025WVE

AI NewsQuantum ComputingBiotechnology

Quantum Entanglement Detection Breakthrough at LHC and €27.5M Funding for Photonic Chips

Quantum entanglement detection at LHC and €27.5M funding for photonic chips drive quantum tech scaling.

Dec 6, 2025

Stock Weather AIBiotechnologyClinical Trials

Praxis Precision Medicines – 2025-12-05 - Increase Confidence 8/10

Negative free cash flow offset by $567M capital raise and positive Phase 3 data for ulixacaltamide drive near-term upside potential.

Dec 5, 2025PRAX

AI NewsBiotechnologyClimate Resilience

AlphaFold Enables Heat-Resilient Crops via GLYK Enzyme Engineering

AlphaFold predicts GLYK enzyme structures, enabling heat-tolerant crops stable at 65°C.

Dec 4, 2025

Stock Weather AIBiotechnologyClinical Catalysts

Beam Therapeutics – 2025-12-04 - Increase Confidence 8/10

Strong cash runway and upcoming ASH data catalyst for BEAM-101 drive near-term upside potential despite negative free cash flow.

Dec 4, 2025BEAM

Stock Weather AIBiotechnologyClinical Trials

Spyre Therapeutics – 2025-12-04 - Increase Confidence 7/10

Strong cash infusion from recent offering combined with first patient enrollment in Phase 2 SKYWAY trial signals near-term momentum, supporting stock price increase.

Dec 4, 2025SYRE

Stock Weather AIBiotechnologyClinical Stage Therapeutics

Spyre Therapeutics – 2025-12-03 - increase Confidence 7/10

Negative free cash flow offset by strong analyst consensus and recent corporate repositioning in IBD space suggests near-term upside on sentiment-driven momentum.

Dec 3, 2025SYRE

Stock Weather AIBiotechnologyMarket Sentiment

Belite Bio – 2025-12-02 - decrease Confidence 3/10

Negative free cash flow of $29.4M clashes with Mizuho’s Hold rating and $105 target; stock at $154.02 faces near-term downside risk despite Strong Buy consensus.

Dec 2, 2025BLTE

Stock Weather AIBiotechnologyM&A Speculation

Jyong Biotech Ltd. – 2025-12-02 - increase Confidence 6/10

Negative free cash flow contrasts with strategic LOI news for MCS-2 in South Korea, creating near-term speculative upside.

Dec 2, 2025MENS

Stock Weather AIBiotechnologyClinical Stage

Vera Therapeutics – 2025-12-02 - Increase Confidence 8/10

Strong cash position and recent BLA submission for atacicept, combined with positive Phase 3 data, signal near-term upside despite negative free cash flow.

Dec 2, 2025VERA

Stock Weather AIBiotechnologyHealthcare

Arrowhead Pharmaceuticals – 2025-11-28 - increase Confidence 6/10

Positive free cash flow and robust late-stage pipeline signal strength, but high debt and generic competition risk cap near-term upside.

Nov 28, 2025ARWR

Stock Weather AIBiotechnologyClinical Stage

Vera Therapeutics – 2025-11-27 - Increase Confidence 8/10

Positive Phase 3 trial data and imminent BLA submission converge with strong institutional backing, signaling near-term upside for VERA.

Nov 27, 2025VERA

Stock Weather AIBiotechnologyClinical Trials

Belite Bio – 2025-11-26 - increase Confidence 6/10

Negative free cash flow contrasts with imminent Q3 2025 business update, creating event-driven upside potential for BLTE in the short term.

Nov 26, 2025BLTE

Stock Weather AIBiotechnologyClinical Trials

Jyong Biotech Ltd. – 2025-11-26 - increase Confidence 7/10

Negative free cash flow contrasts with imminent Phase II trial data readout for MCS-8, creating catalyst-driven upside potential in the near term.

Nov 26, 2025MENS

AI NewsBiotechnologyHealthcare

AlphaFold Reveals a Key Protein Behind Heart Disease

AlphaFold maps apoB100, the protein central to 'bad cholesterol,' unlocking new avenues for heart disease treatment.

Nov 25, 2025

Stock Weather AIBiotechnologyHealthcare

Adaptive Biotechnologies – 2025-11-21 - Increase Confidence 7/10

Improving losses and strong MRD revenue growth meet favorable CMS reimbursement, fueling near-term upside despite high leverage.

Nov 21, 2025ADPT

Stock Weather AIBiotechnologyMarket Momentum

ABIVAX – 2025-11-20 - increase Confidence 6/10

Negative free cash flow contrasts with strong analyst upgrades and 1,193% YTD surge, fueling momentum-driven upside potential in the near term.

Nov 20, 2025ABVX

Stock Weather AIBiotechnologyHealthcare

Jyong Biotech Ltd. – 2025-11-20 - increase Confidence 7/10

Negative free cash flow contrasts with FDA NDA submission and recent Nasdaq listing, creating near-term catalyst potential for stock appreciation.

Nov 20, 2025MENS

Stock Weather AIBiotechnologyClinical Trials

Jazz Pharmaceuticals – 2025-11-18 - Increase Confidence 9/10

Strong free cash flow and record-breaking Phase 3 trial success for Ziihera drive near-term upside potential.

Nov 18, 2025JAZZ

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-11-18 - Increase Confidence 8/10

Negative free cash flow persists, but $799M cash runway and imminent Phase 2b obesity data create high-impact catalyst for stock upside.

Nov 18, 2025GPCR

Stock Weather AIBiotechnologyClinical Trials

Jyong Biotech Ltd. – 2025-11-18 - increase Confidence 6/10

Negative free cash flow contrasts with imminent Phase II trial data readout for MCS-8, creating near-term catalyst-driven upside potential.

Nov 18, 2025MENS

Stock Weather AIBiotechnologyClinical Trials

Nuvalent – 2025-11-18 - Increase Confidence 8/10

Negative free cash flow contrasts with strong clinical trial results and FDA engagement plans, fueling near-term upside potential.

Nov 18, 2025NUVL